SlideShare a Scribd company logo
1 of 10
Dr Sue E Shajan
Dr. SUE ELIZABETH SHAJAN
Microbiologist [In-Charge of Microbiology]
sueshajan@gmail.com
Mobile # 00-966-509070341
______________________________________________________________________
SUMMARY OF QUALIFICATIONS
• Pursuing a PhD and Post Graduate diploma in Medical Microbiology.
• Obtained More than 23 years of hospital experience in the field of Medical / Clinical
Microbiology. [ Relevant experience in GLP/GCP/GRP/GDP]
• Tailored in Microbiological laboratory like Clinical Bacteriology, Mycobacteriology,
Mycology, Serology, Virology, and Parasitology.
• As a clinical microbiologist in a health care setting, identify pathogens and diseases to
protect the hospital and community from the spread of infectious diseases.
• Responsible for evaluation of procedures, interpretation of results, including plate
reading and diagnosing the aetiological agents, antimicrobial susceptibility results where
indicated and discuss with clinicians on the treatment of infected patients. And for
surveillance of restricted antimicrobial use and its data for every quarter.
• Experienced in Laboratory Organization, Restricted Antibiotic formulary approval,
Quality control of antibiotics, reagents and verify all microbiological test methods and
Strong Microbiology Management.
• Executed the surveillance methods of hospital supplies, sterilizers, environment,
Pharmacist prepared IV fluids quality control and water culture methods.
• Presenting the findings of research, supervising the work of support staff and carrying
out the administrative work and also involved in tutoring and mentoring.
EDUCATION PROFILE
PhD in Clinical Microbiology 2011-2015
Karpagam University, Coimbatore, India. Holding a Ph.D Certificate
Dissertation title: “Passive therapeutic approach using Chicken Egg Yolk (IgY)
Antibodies against Clostridium difficile and its prevalence in Jubail, Saudi Arabia”
MRCP (PART–I Exam) Medical Microbiology 2007 1stAttempt
Royal College of Pathologist, London.
1
Dr Sue E Shajan
Post Graduate Diploma in Medical Microbiology 1989 -1990
Christian Medical College and Hospital, Vellore, India.
Master of Science in Botany 1987-1989
Bharathiar University, TamilNadu, India.
Dissertation title: “Effect of fungicides on Rhizobium-Dolihos lab lab Symbiosis”
Bachelor of Science in Botany 1984-1987
Bharathiar University, TamilNadu, India
PROFESSIONAL ACHIEVEMENTS
Microbiologist / In charge of Microbiology May 2001 to Present
Al Mana General Hospital, [First 5 years Locum]
(JCAHO-CBAHI Standards) Jubail, Saudi Arabia.
Microbiologist Feb1994 to Oct 1998
Al Fanateer Royal Commission Hospital
(JCAHO Standards) Jubail, Saudi Arabia.
Microbiologist Oct 1993 to Jan1994
M.G.D.M. Hospital, Kangazha, Kerala, India
Intern, Junior Microbiologist Aug1990 to Oct 1993
&
Staff /Senior Microbiologist
Christian Medical College and Hospital,
Vellore, Tamil Nadu, India
SKILLS AND RESPONSIBILITIES
• Creating and directing an accredited clinical/diagnostic laboratory service, both
operationally and financially, that will support and improve the clinical diagnosis and
epidemiological investigation of infectious diseases.
• Generating, disseminating and interpreting data from microbiological investigations as
they apply to the diagnosis, management, and treatment of patients with infectious
diseases and public health scenarios involving infectious diseases.
• Developing and supporting accredited microbiology training programs for
Clinical/Medical professional and technical personnel.
• Establishing and supporting microbiological research programs that advance the field of
infectious diseases for improved patient care and public health.
2
Dr Sue E Shajan
• Acting as a microbiology consultant to support clinical and public health Programs
/initiatives at the local, national and international level.
• JCIA AND CBAHI Standards of accreditation, assigned for the supervisory team
work.
• Privileges to perform emergency life- saving procedure are automatically granted to all
medical staff. Holding a valid BLS certification.
• Computer Skill Packages: MS Office (Word, Excel and Power point).
SCOPE OF ACTIVITIES
• Consultation with other healthcare providers regarding specimen collection, the
selection and interpretation of clinical microbiology tests/results, including
antimicrobial susceptibility, infection control, and public health facilities.
• Direction and assistance for medical technologists with the interpretation of the Clinical
significance of laboratory findings
• Development and support of an effective quality assurance and quality management
program for all laboratory services.
• Provision of technical troubleshooting and problem solving, ensure the production of
reliable and accurate laboratory results and reports.
• Leading of hospital laboratory information systems management, practice guideline
development, and personnel safety and management. Liaising with laboratory
administration and personnel, Conducting cost-efficacy analyses on new diagnostic
systems and algorithms.
• Overseeing accreditation, competency, proficiency testing, and overall quality
performance of the microbiology laboratory service and lead strategic planning
initiatives.
• Executed the surveillance methods of hospital supplies, sterilizers, environment,
monitoring of Pharmacy laminar flow hood with prepared IV fluids quality control, and
water culture methods.
• As academic and scientific leaders, expected to be actively involved in research activities
within the academic and scientific area.
• Development/evaluation/implementation of new test methods, techniques and
3
Dr Sue E Shajan
Instrumentation Collaboration with clinical/basic research colleagues
• Fostered interest in and to facilitate knowledge transfer of microbiology by engaging in
educational endeavors.
• Provision of formal and informal teaching of clinical/medical professionals, technical
staffs. Expected to support and promote their profession at the local, national and
international level and perform all of the duties in an ethical and honest manner.
ACADEMIC ACTIVITIES
Journal Publications
1. Sue E.Shajan., M.H.Faisal and A.Michael Alert!!! Beware of Mobile Phones!!! Has A
Great Role in Disease Transmission, Clean them up!!!! Safe to Handle…Int J Med
Research and Health Science., 2013: 2 (3):582-588.
2. Sue E.Shajan., M.H.Faisal and A .Michael Prevalence of Clostridium difficile toxin in
diarrhoeal stool samples of patients from a general hospital in Eastern Province,
Saudi Arabia. Int J Med Res Health Sci., 2014 : 3 (2):302-308.
3. Sue E.Shajan., A.Michael and M.Ramasmay Generation and Characterization of
chicken egg yolk Antibodies (IgY) against Clostridium difficile and evaluating its
invitro neutralization efficacy. World Journal of Pharmaceutical Research., 2014 3 (10): 646-
665. Impact Factor 5.045.
4. Bright Varghese, Sue Elizabeth Shajan, Majed Omar Al Saedi and Sahal A. Al-Hajoja
First case report of chronic pulmonary lung disease caused by Mycobacterium
abscesses in two immunocompetent patients in Saudi Arabia. Annals of Saudi Medicine
2012; 32(3): 312 May-June www.annsaudimed.net
Invited and Conference Presentations
1. Drug Resistance in TB Presented to Ministry of Health laboratories at Eastern Province, Saudi
Arabia.2013.
2. National Conference on Recent Developments in Microbiology, Biochemistry &
Biotechnology. Participated & Presented a paper in Clostridium difficile Study. PSG
College of Arts & Science, Coimbatore. India; 2013.
3. Alert!!! Beware of Mobile Phones!!! Has A Great Role in Disease Transmission,
Clean them up!!! Safe to Handle. 4th
Annual Research Conferences KUARC, Coimbatore. India;
2012.
4
Dr Sue E Shajan
4. Prevalence of Clostridium difficile toxin in diarrhoeal stool samples of patients
from a general hospital in Eastern Province, Saudi Arabia. 5th
Annual Research Conferences
KUARC, Coimbatore. India; 2013.
5. Generation and Characterization of chicken egg yolk Antibodies (IgY) against
Clostridium difficile and evaluating its in-vitro neutralization efficacy. 6th
Annual
Research Conferences KUARC, Coimbatore. India; 2014.
Abroad (Saudi Arabia) attended activities
1. June 4-5& 6-8 2011 - 31 CME hrs – “Basic and Advanced Molecular Biology Techniques
in Diagnostic Laboratories”Prince Sultan Military College of Health Sciences-Dhahran, Saudi Arabia
-2011.
2. Oct 02-03-2012 - 15 CME hrs- Antibiotic Prescribing & Treating Common Infections in
Primary Care Setting & Inpatient Setting. Saudi Society of Medical Microbiology & Infectious Diseases
with King Fahad Hospital ,Hofuf, Saudi Arabia 2012
3. March 7-3-12 to 26-12-1-10 CME hrs- CME/PD Series of Lectures 2012 Al Mana General
Hospital, Al Ahasa. 2012
4. Jan 08-09-2013 - 15 CME hrs-The Antimicrobial Workshop Saudi Society of Medical
Microbiology& Infectious Diseases, University-of Dammam.
5. March24-2013 4CME hrs Challenges in the Global Elimination of TB Role of Regional
lab TB. Ministry of Health laboratories at Eastern Province, Regional lab, Dammam, SaudiArabia-2013
6. Jan 9-13 to Dec 25 -2013 - 10 CME hrs CME/PD Series of Lectures-2013 Al Mana General
Hospital, Al Ahasa. 2013
7. Feb 19-14 to Feb 19- 2014 Certificate of Cardiopulmonary Resuscitation.BLS Provider
Saudi Heart Association. National CPR Committee.
8. May 01 -2014 - 6 CME hrs Asthma Awareness Day. National Guard Health Affairs, Eastern
Province.
9. April 16,17 -2015 - 10CME hrs Sepsis in ICU What We Should Know King Fahad Hospital , Al
Baha
10. May 29 2015 - 8 CME hrs Update in Infectious Diseases Symposium Saad Specialist Hospital.
Alkhobar
11. July 28 2015 - 5 CME hrs Sepsis in ICU What We Should Know. King Fahad Specialist
Hospital, Dammam.
12. Nov 22, 2015 – Pharmaceutical care Department Antibiotic Awareness Day
5
Dr Sue E Shajan
Ministry of Health, Dammam Medical Complex
Research Proposal Pursuits
Passive Therapeutic Approach using Chicken Egg Yolk (IgY) Antibodies against C.difficile
and it’s Prevalence in Jubail, Saudi Arabia.
Objectives
1. To characterize the patients samples for screening, isolation, different methods of
biochemical identification and detection of Clostridium difficile Toxin A & B
2. To collect the demographic and clinical parameters of the isolates to investigate the
prevalence of Clostridium difficile infections.
3. To generate and characterize the chicken egg yolk antibodies (IgY) against Clostridium
difficile.
4. To determine the specificity, quantitative titration of antibodies by ELISA, and analyze
the protein profile of anti- Clostridium difficile IgY antibodies by SDS PAGE.
5. To determine the physicochemical properties, stability and the neutralization efficacy of
Clostridium diffiicle-specific IgY by in-vitro growth inhibition methods
Summary
The detection of CDT in the diagnosis of CDI requires vigilance by both clinician and
Microbiologist to look out for possible infected patients. Antibiotic usage is a known risk factor;
thus restricted use of antibiotics may results the reduction of CDI. In this study the prevalence of
CDAD was 0.3 and 0.2 per 10,000 patient days in 2011 and 2012; this rate is lower than the
prevalence rates reported from the other countries. Mainly due to the strict implementation of
restricted antibiotic guidelines, before starting any restricted antibiotics, the antibiotic form must be
approved by the Microbiologist, may consider with minimum level compatible with effective
therapy. This study explore that each hospital must strictly use the antibiotic guidelines to encourage
the rational use of antibiotics and reducing the unnecessary use of antibiotics helps to slow down the
evolution of microbial antibiotic resistance. And also encourage the use of alternative antibiotics,
which are less toxic and less expensive.
The present investigation is focused to generate chicken egg yolk antibodies against C.difficile. A
standard isolate of Clostridium difficile procured from American Type Culture Collection (ATCC 9689)
was used for the in-vitro study. The strain was characterized morphologically and biochemically. The
C.difficile culture was also identified by the VITEK 2 automated microbial detection systems. The
6
Dr Sue E Shajan
systems accommodate the colorimetric reagent cards that are incubated and the results are
interpreted automatically. Clostridiumdifficile whole cell antigen was prepared and viability and purity
of antigen was checked. The white leghorn chickens were intramuscularly immunized with whole
cell antigen comprising of Clostridium difficile emulsified with Freund’s adjuvant. Periodically the
booster doses were given at every 2weeks of interval till the antibody level reaches a plateau. The
antibodies generated from the chicken immunized with the antigen were purified from the egg yolk
by Polson et al., (1980). Protein and total IgY concentration were estimated. The average
concentration of protein and total IgY were 39.99 ± 0.79 mg/ ml and 15.26 ± 0.57 mg/ml for
C.difficile Purity of IgY was determined by SDS-PAGE, in which, 180KDa protein bands were
observed. Specific reactivity of IgY with respective antigen was assessed by agglutinating capacity in
the rapid slide agglutination test. Titer of specific IgY in egg yolk was estimated by ELISA. The
higher titre of 1:100000 were estimated on 91st day were maintained with booster doses. In order to
evaluate the efficacy of IgY- C.difficile in preventing and treatment of C.difficile infection and the
stability in humans was investigated at different physicochemical properties. Anti-C.difficile IgY was
found to be stable at the temperature of 4°C, 10ºC, 25°C, 37ºC and pH ranging between 4.0 and 9.0.
The stability level of IgY shows its ability to withstand the intestinal acidic condition.
Growth inhibition assay was performed to determine whether the binding activity of anti- Clostridium
difficile IgY could inhibit the C.difficile growth in the liquid medium. There was a significant reduction
in the growth of Clostridium difficile after 16 hours of incubation. Antibiotics are not only important to
cure infections, although resistance is increasing, development of new antibiotics is also decreasing..
Likewise, a number of studies and case reports have indicated that passive immunotherapy is a
successful therapy for patients suffering chronic relapsing C.difficile infection, which did not respond
to standard treatment (i.e., antibiotic therapy). Here in this study we contend that colonizing factor
specific IgY preparation, either alone or in combination with other therapeutic strategies, depict for
treating CDI because they can be mass-produced inexpensively, and they are listed in a safe category
for human use. Passive immunization by oral administration of specific antibodies in a capsule form
has been an attractive approach against gastrointestinal tract (GIT) pathogens in both humans and
animals. These studies indicate that eggs from chickens immunized with appropriate antigens are
potentially a useful of passive immunity. In the future studies the antibody that harvested against
antigenic component of C. difficile can be incorporated as prophylactic and passive therapeutic agent.
However more intense studies are to be done for successful application of egg derived antibody.
7
Dr Sue E Shajan
Passive immunotherapy with specific IgY may be a promising alternative with high specific natural
and low cost effective.
Awards and Honors Lists
• PhD Mark List & Degree Certificate.
• World Education Service – US equivalency Evaluation Report
• Diploma in Medical Microbiology
• M.Sc certificates
• B.Sc Certificates.
Certification
• In Charge Of Microbiology Certificate
• BLS Certificate
• Certificate of Appreciation MOH LAB
• CBAHI, JCIA and Quality Control
• All Experience Certificates:
References
Dr. Elizabeth Mathai [WHO Officer, Geneva]
Department of Clinical Microbiology
CMCH, Vellore.
0041794056602
Relationship: Professor and Mentor for 5 years
Dr. A.Michael
Department of Microbiology,
PSG College of Arts& Science,
Coimbatore, Tamil Nadu, India
00919842223414, amichela2000@gmail.com
Relationship: Ph.D. Guide for 5 years
Dr. M.Palaniswamy
Department of Microbiology
Karpagam University
Coimbatore, Tamil Nadu, India
00919894736777, m.palaniswamy@gmail.com
Relationship: Ph.D. Advisor for 5 years
Dr. Faisal.H.M
Chief of Medical Staff,
Department of Medicine,
Al Mana General Hospital,
8
Dr Sue E Shajan
Al Jubail, Saudi Arabia
00966504967427, fahms91@hotmail.com
Relationship: Hospital Medical director and Ph.D. Co-guide for total 15 years.
Declaration
I solemnly declare that the above information furnished here are true to the best of my knowledge
and belief.
Signature of the Applicant
(SUE ELIZABETH SHAJAN)
9
Dr Sue E Shajan
Al Jubail, Saudi Arabia
00966504967427, fahms91@hotmail.com
Relationship: Hospital Medical director and Ph.D. Co-guide for total 15 years.
Declaration
I solemnly declare that the above information furnished here are true to the best of my knowledge
and belief.
Signature of the Applicant
(SUE ELIZABETH SHAJAN)
9

More Related Content

What's hot

T cell mediated immune response Rashmi PGI 2022
T cell mediated immune response Rashmi PGI 2022T cell mediated immune response Rashmi PGI 2022
T cell mediated immune response Rashmi PGI 2022RashmiRikhi1
 
Introduction to Immunology
Introduction to ImmunologyIntroduction to Immunology
Introduction to ImmunologyMilan Taradi
 
Antigens, Haptens and Adjuvants
Antigens, Haptens and AdjuvantsAntigens, Haptens and Adjuvants
Antigens, Haptens and AdjuvantsSaranraj P
 
Fresher java j2ee resume
Fresher java j2ee resumeFresher java j2ee resume
Fresher java j2ee resumeVikram Rawani
 
Stem cell technology | Presented by pranjali V. Bhadane
Stem cell technology | Presented by pranjali V. BhadaneStem cell technology | Presented by pranjali V. Bhadane
Stem cell technology | Presented by pranjali V. Bhadanepranjali bhadane
 
Cells involved in Immunity
Cells involved in ImmunityCells involved in Immunity
Cells involved in ImmunityAtifa Ambreen
 
Cloning
Cloning Cloning
Cloning Afael
 
Monoclonal Antibody Production via Hybridoma Technology
Monoclonal Antibody Production via Hybridoma TechnologyMonoclonal Antibody Production via Hybridoma Technology
Monoclonal Antibody Production via Hybridoma TechnologyKathryn Howard
 
Hematopoietic Stem Cells Transplantation
Hematopoietic Stem Cells TransplantationHematopoietic Stem Cells Transplantation
Hematopoietic Stem Cells Transplantationbiomedicz
 
Immuno haematology
Immuno haematologyImmuno haematology
Immuno haematologyrabbibaidoo
 
Primary and Secondary Immune Responses
Primary and Secondary Immune Responses Primary and Secondary Immune Responses
Primary and Secondary Immune Responses AhmedRiyadh17
 
Cancer and immune system
Cancer and immune systemCancer and immune system
Cancer and immune systemNidaSajjad2
 

What's hot (20)

Stem cell therapy
Stem cell therapyStem cell therapy
Stem cell therapy
 
T cell mediated immune response Rashmi PGI 2022
T cell mediated immune response Rashmi PGI 2022T cell mediated immune response Rashmi PGI 2022
T cell mediated immune response Rashmi PGI 2022
 
Introduction to Immunology
Introduction to ImmunologyIntroduction to Immunology
Introduction to Immunology
 
Antigens, Haptens and Adjuvants
Antigens, Haptens and AdjuvantsAntigens, Haptens and Adjuvants
Antigens, Haptens and Adjuvants
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
 
B Lymphocytes
B Lymphocytes B Lymphocytes
B Lymphocytes
 
Dendritic cells
Dendritic cellsDendritic cells
Dendritic cells
 
Fresher java j2ee resume
Fresher java j2ee resumeFresher java j2ee resume
Fresher java j2ee resume
 
Milk and Meat.pptx
Milk and Meat.pptxMilk and Meat.pptx
Milk and Meat.pptx
 
Stem cell technology | Presented by pranjali V. Bhadane
Stem cell technology | Presented by pranjali V. BhadaneStem cell technology | Presented by pranjali V. Bhadane
Stem cell technology | Presented by pranjali V. Bhadane
 
Cells of immune system
Cells of immune systemCells of immune system
Cells of immune system
 
Cells involved in Immunity
Cells involved in ImmunityCells involved in Immunity
Cells involved in Immunity
 
Cloning
Cloning Cloning
Cloning
 
Monoclonal Antibody Production via Hybridoma Technology
Monoclonal Antibody Production via Hybridoma TechnologyMonoclonal Antibody Production via Hybridoma Technology
Monoclonal Antibody Production via Hybridoma Technology
 
Hematopoietic Stem Cells Transplantation
Hematopoietic Stem Cells TransplantationHematopoietic Stem Cells Transplantation
Hematopoietic Stem Cells Transplantation
 
Autoimmune disorders
Autoimmune disordersAutoimmune disorders
Autoimmune disorders
 
Immunocompetence tests
Immunocompetence testsImmunocompetence tests
Immunocompetence tests
 
Immuno haematology
Immuno haematologyImmuno haematology
Immuno haematology
 
Primary and Secondary Immune Responses
Primary and Secondary Immune Responses Primary and Secondary Immune Responses
Primary and Secondary Immune Responses
 
Cancer and immune system
Cancer and immune systemCancer and immune system
Cancer and immune system
 

Similar to Dr. SUE ELIZABETH SHAJAN CV 2016[1]

Similar to Dr. SUE ELIZABETH SHAJAN CV 2016[1] (20)

DOC-20161023-cv
DOC-20161023-cvDOC-20161023-cv
DOC-20161023-cv
 
MANOJ KUMAR CV latest link
MANOJ KUMAR CV latest linkMANOJ KUMAR CV latest link
MANOJ KUMAR CV latest link
 
Curriculum vitae
Curriculum vitaeCurriculum vitae
Curriculum vitae
 
Amen_Bawazir_CV Jan 2017
Amen_Bawazir_CV Jan 2017Amen_Bawazir_CV Jan 2017
Amen_Bawazir_CV Jan 2017
 
c v
c vc v
c v
 
Samuel's CV.
Samuel's CV.Samuel's CV.
Samuel's CV.
 
Dr Viral Shah
Dr Viral Shah Dr Viral Shah
Dr Viral Shah
 
milad farzin CV
milad farzin CVmilad farzin CV
milad farzin CV
 
2016-02-11 - CV Grace Najjuka - Modified (Autosaved)-2
2016-02-11 - CV Grace Najjuka - Modified (Autosaved)-22016-02-11 - CV Grace Najjuka - Modified (Autosaved)-2
2016-02-11 - CV Grace Najjuka - Modified (Autosaved)-2
 
Swarupa konduru resume
Swarupa konduru resumeSwarupa konduru resume
Swarupa konduru resume
 
Rahul Resume - RA CV
Rahul Resume - RA CVRahul Resume - RA CV
Rahul Resume - RA CV
 
Microbioloy and clinical interaction ...
Microbioloy and clinical interaction                                         ...Microbioloy and clinical interaction                                         ...
Microbioloy and clinical interaction ...
 
Largest laboratory conference in the Middle East
Largest laboratory conference in the Middle EastLargest laboratory conference in the Middle East
Largest laboratory conference in the Middle East
 
Current cv2016 (2)
Current cv2016 (2)Current cv2016 (2)
Current cv2016 (2)
 
DrSurendraCurrentCV
DrSurendraCurrentCVDrSurendraCurrentCV
DrSurendraCurrentCV
 
Soumili bhaduri tagore cv
Soumili bhaduri tagore cvSoumili bhaduri tagore cv
Soumili bhaduri tagore cv
 
SRIKANTH VUYYURU_original
SRIKANTH VUYYURU_originalSRIKANTH VUYYURU_original
SRIKANTH VUYYURU_original
 
CV updated New 2015
CV updated New 2015CV updated New 2015
CV updated New 2015
 
RACHELODONOVANCV
RACHELODONOVANCVRACHELODONOVANCV
RACHELODONOVANCV
 
11_General Clinical Microbiology.pdf
11_General Clinical Microbiology.pdf11_General Clinical Microbiology.pdf
11_General Clinical Microbiology.pdf
 

Dr. SUE ELIZABETH SHAJAN CV 2016[1]

  • 1. Dr Sue E Shajan Dr. SUE ELIZABETH SHAJAN Microbiologist [In-Charge of Microbiology] sueshajan@gmail.com Mobile # 00-966-509070341 ______________________________________________________________________ SUMMARY OF QUALIFICATIONS • Pursuing a PhD and Post Graduate diploma in Medical Microbiology. • Obtained More than 23 years of hospital experience in the field of Medical / Clinical Microbiology. [ Relevant experience in GLP/GCP/GRP/GDP] • Tailored in Microbiological laboratory like Clinical Bacteriology, Mycobacteriology, Mycology, Serology, Virology, and Parasitology. • As a clinical microbiologist in a health care setting, identify pathogens and diseases to protect the hospital and community from the spread of infectious diseases. • Responsible for evaluation of procedures, interpretation of results, including plate reading and diagnosing the aetiological agents, antimicrobial susceptibility results where indicated and discuss with clinicians on the treatment of infected patients. And for surveillance of restricted antimicrobial use and its data for every quarter. • Experienced in Laboratory Organization, Restricted Antibiotic formulary approval, Quality control of antibiotics, reagents and verify all microbiological test methods and Strong Microbiology Management. • Executed the surveillance methods of hospital supplies, sterilizers, environment, Pharmacist prepared IV fluids quality control and water culture methods. • Presenting the findings of research, supervising the work of support staff and carrying out the administrative work and also involved in tutoring and mentoring. EDUCATION PROFILE PhD in Clinical Microbiology 2011-2015 Karpagam University, Coimbatore, India. Holding a Ph.D Certificate Dissertation title: “Passive therapeutic approach using Chicken Egg Yolk (IgY) Antibodies against Clostridium difficile and its prevalence in Jubail, Saudi Arabia” MRCP (PART–I Exam) Medical Microbiology 2007 1stAttempt Royal College of Pathologist, London. 1
  • 2. Dr Sue E Shajan Post Graduate Diploma in Medical Microbiology 1989 -1990 Christian Medical College and Hospital, Vellore, India. Master of Science in Botany 1987-1989 Bharathiar University, TamilNadu, India. Dissertation title: “Effect of fungicides on Rhizobium-Dolihos lab lab Symbiosis” Bachelor of Science in Botany 1984-1987 Bharathiar University, TamilNadu, India PROFESSIONAL ACHIEVEMENTS Microbiologist / In charge of Microbiology May 2001 to Present Al Mana General Hospital, [First 5 years Locum] (JCAHO-CBAHI Standards) Jubail, Saudi Arabia. Microbiologist Feb1994 to Oct 1998 Al Fanateer Royal Commission Hospital (JCAHO Standards) Jubail, Saudi Arabia. Microbiologist Oct 1993 to Jan1994 M.G.D.M. Hospital, Kangazha, Kerala, India Intern, Junior Microbiologist Aug1990 to Oct 1993 & Staff /Senior Microbiologist Christian Medical College and Hospital, Vellore, Tamil Nadu, India SKILLS AND RESPONSIBILITIES • Creating and directing an accredited clinical/diagnostic laboratory service, both operationally and financially, that will support and improve the clinical diagnosis and epidemiological investigation of infectious diseases. • Generating, disseminating and interpreting data from microbiological investigations as they apply to the diagnosis, management, and treatment of patients with infectious diseases and public health scenarios involving infectious diseases. • Developing and supporting accredited microbiology training programs for Clinical/Medical professional and technical personnel. • Establishing and supporting microbiological research programs that advance the field of infectious diseases for improved patient care and public health. 2
  • 3. Dr Sue E Shajan • Acting as a microbiology consultant to support clinical and public health Programs /initiatives at the local, national and international level. • JCIA AND CBAHI Standards of accreditation, assigned for the supervisory team work. • Privileges to perform emergency life- saving procedure are automatically granted to all medical staff. Holding a valid BLS certification. • Computer Skill Packages: MS Office (Word, Excel and Power point). SCOPE OF ACTIVITIES • Consultation with other healthcare providers regarding specimen collection, the selection and interpretation of clinical microbiology tests/results, including antimicrobial susceptibility, infection control, and public health facilities. • Direction and assistance for medical technologists with the interpretation of the Clinical significance of laboratory findings • Development and support of an effective quality assurance and quality management program for all laboratory services. • Provision of technical troubleshooting and problem solving, ensure the production of reliable and accurate laboratory results and reports. • Leading of hospital laboratory information systems management, practice guideline development, and personnel safety and management. Liaising with laboratory administration and personnel, Conducting cost-efficacy analyses on new diagnostic systems and algorithms. • Overseeing accreditation, competency, proficiency testing, and overall quality performance of the microbiology laboratory service and lead strategic planning initiatives. • Executed the surveillance methods of hospital supplies, sterilizers, environment, monitoring of Pharmacy laminar flow hood with prepared IV fluids quality control, and water culture methods. • As academic and scientific leaders, expected to be actively involved in research activities within the academic and scientific area. • Development/evaluation/implementation of new test methods, techniques and 3
  • 4. Dr Sue E Shajan Instrumentation Collaboration with clinical/basic research colleagues • Fostered interest in and to facilitate knowledge transfer of microbiology by engaging in educational endeavors. • Provision of formal and informal teaching of clinical/medical professionals, technical staffs. Expected to support and promote their profession at the local, national and international level and perform all of the duties in an ethical and honest manner. ACADEMIC ACTIVITIES Journal Publications 1. Sue E.Shajan., M.H.Faisal and A.Michael Alert!!! Beware of Mobile Phones!!! Has A Great Role in Disease Transmission, Clean them up!!!! Safe to Handle…Int J Med Research and Health Science., 2013: 2 (3):582-588. 2. Sue E.Shajan., M.H.Faisal and A .Michael Prevalence of Clostridium difficile toxin in diarrhoeal stool samples of patients from a general hospital in Eastern Province, Saudi Arabia. Int J Med Res Health Sci., 2014 : 3 (2):302-308. 3. Sue E.Shajan., A.Michael and M.Ramasmay Generation and Characterization of chicken egg yolk Antibodies (IgY) against Clostridium difficile and evaluating its invitro neutralization efficacy. World Journal of Pharmaceutical Research., 2014 3 (10): 646- 665. Impact Factor 5.045. 4. Bright Varghese, Sue Elizabeth Shajan, Majed Omar Al Saedi and Sahal A. Al-Hajoja First case report of chronic pulmonary lung disease caused by Mycobacterium abscesses in two immunocompetent patients in Saudi Arabia. Annals of Saudi Medicine 2012; 32(3): 312 May-June www.annsaudimed.net Invited and Conference Presentations 1. Drug Resistance in TB Presented to Ministry of Health laboratories at Eastern Province, Saudi Arabia.2013. 2. National Conference on Recent Developments in Microbiology, Biochemistry & Biotechnology. Participated & Presented a paper in Clostridium difficile Study. PSG College of Arts & Science, Coimbatore. India; 2013. 3. Alert!!! Beware of Mobile Phones!!! Has A Great Role in Disease Transmission, Clean them up!!! Safe to Handle. 4th Annual Research Conferences KUARC, Coimbatore. India; 2012. 4
  • 5. Dr Sue E Shajan 4. Prevalence of Clostridium difficile toxin in diarrhoeal stool samples of patients from a general hospital in Eastern Province, Saudi Arabia. 5th Annual Research Conferences KUARC, Coimbatore. India; 2013. 5. Generation and Characterization of chicken egg yolk Antibodies (IgY) against Clostridium difficile and evaluating its in-vitro neutralization efficacy. 6th Annual Research Conferences KUARC, Coimbatore. India; 2014. Abroad (Saudi Arabia) attended activities 1. June 4-5& 6-8 2011 - 31 CME hrs – “Basic and Advanced Molecular Biology Techniques in Diagnostic Laboratories”Prince Sultan Military College of Health Sciences-Dhahran, Saudi Arabia -2011. 2. Oct 02-03-2012 - 15 CME hrs- Antibiotic Prescribing & Treating Common Infections in Primary Care Setting & Inpatient Setting. Saudi Society of Medical Microbiology & Infectious Diseases with King Fahad Hospital ,Hofuf, Saudi Arabia 2012 3. March 7-3-12 to 26-12-1-10 CME hrs- CME/PD Series of Lectures 2012 Al Mana General Hospital, Al Ahasa. 2012 4. Jan 08-09-2013 - 15 CME hrs-The Antimicrobial Workshop Saudi Society of Medical Microbiology& Infectious Diseases, University-of Dammam. 5. March24-2013 4CME hrs Challenges in the Global Elimination of TB Role of Regional lab TB. Ministry of Health laboratories at Eastern Province, Regional lab, Dammam, SaudiArabia-2013 6. Jan 9-13 to Dec 25 -2013 - 10 CME hrs CME/PD Series of Lectures-2013 Al Mana General Hospital, Al Ahasa. 2013 7. Feb 19-14 to Feb 19- 2014 Certificate of Cardiopulmonary Resuscitation.BLS Provider Saudi Heart Association. National CPR Committee. 8. May 01 -2014 - 6 CME hrs Asthma Awareness Day. National Guard Health Affairs, Eastern Province. 9. April 16,17 -2015 - 10CME hrs Sepsis in ICU What We Should Know King Fahad Hospital , Al Baha 10. May 29 2015 - 8 CME hrs Update in Infectious Diseases Symposium Saad Specialist Hospital. Alkhobar 11. July 28 2015 - 5 CME hrs Sepsis in ICU What We Should Know. King Fahad Specialist Hospital, Dammam. 12. Nov 22, 2015 – Pharmaceutical care Department Antibiotic Awareness Day 5
  • 6. Dr Sue E Shajan Ministry of Health, Dammam Medical Complex Research Proposal Pursuits Passive Therapeutic Approach using Chicken Egg Yolk (IgY) Antibodies against C.difficile and it’s Prevalence in Jubail, Saudi Arabia. Objectives 1. To characterize the patients samples for screening, isolation, different methods of biochemical identification and detection of Clostridium difficile Toxin A & B 2. To collect the demographic and clinical parameters of the isolates to investigate the prevalence of Clostridium difficile infections. 3. To generate and characterize the chicken egg yolk antibodies (IgY) against Clostridium difficile. 4. To determine the specificity, quantitative titration of antibodies by ELISA, and analyze the protein profile of anti- Clostridium difficile IgY antibodies by SDS PAGE. 5. To determine the physicochemical properties, stability and the neutralization efficacy of Clostridium diffiicle-specific IgY by in-vitro growth inhibition methods Summary The detection of CDT in the diagnosis of CDI requires vigilance by both clinician and Microbiologist to look out for possible infected patients. Antibiotic usage is a known risk factor; thus restricted use of antibiotics may results the reduction of CDI. In this study the prevalence of CDAD was 0.3 and 0.2 per 10,000 patient days in 2011 and 2012; this rate is lower than the prevalence rates reported from the other countries. Mainly due to the strict implementation of restricted antibiotic guidelines, before starting any restricted antibiotics, the antibiotic form must be approved by the Microbiologist, may consider with minimum level compatible with effective therapy. This study explore that each hospital must strictly use the antibiotic guidelines to encourage the rational use of antibiotics and reducing the unnecessary use of antibiotics helps to slow down the evolution of microbial antibiotic resistance. And also encourage the use of alternative antibiotics, which are less toxic and less expensive. The present investigation is focused to generate chicken egg yolk antibodies against C.difficile. A standard isolate of Clostridium difficile procured from American Type Culture Collection (ATCC 9689) was used for the in-vitro study. The strain was characterized morphologically and biochemically. The C.difficile culture was also identified by the VITEK 2 automated microbial detection systems. The 6
  • 7. Dr Sue E Shajan systems accommodate the colorimetric reagent cards that are incubated and the results are interpreted automatically. Clostridiumdifficile whole cell antigen was prepared and viability and purity of antigen was checked. The white leghorn chickens were intramuscularly immunized with whole cell antigen comprising of Clostridium difficile emulsified with Freund’s adjuvant. Periodically the booster doses were given at every 2weeks of interval till the antibody level reaches a plateau. The antibodies generated from the chicken immunized with the antigen were purified from the egg yolk by Polson et al., (1980). Protein and total IgY concentration were estimated. The average concentration of protein and total IgY were 39.99 ± 0.79 mg/ ml and 15.26 ± 0.57 mg/ml for C.difficile Purity of IgY was determined by SDS-PAGE, in which, 180KDa protein bands were observed. Specific reactivity of IgY with respective antigen was assessed by agglutinating capacity in the rapid slide agglutination test. Titer of specific IgY in egg yolk was estimated by ELISA. The higher titre of 1:100000 were estimated on 91st day were maintained with booster doses. In order to evaluate the efficacy of IgY- C.difficile in preventing and treatment of C.difficile infection and the stability in humans was investigated at different physicochemical properties. Anti-C.difficile IgY was found to be stable at the temperature of 4°C, 10ºC, 25°C, 37ºC and pH ranging between 4.0 and 9.0. The stability level of IgY shows its ability to withstand the intestinal acidic condition. Growth inhibition assay was performed to determine whether the binding activity of anti- Clostridium difficile IgY could inhibit the C.difficile growth in the liquid medium. There was a significant reduction in the growth of Clostridium difficile after 16 hours of incubation. Antibiotics are not only important to cure infections, although resistance is increasing, development of new antibiotics is also decreasing.. Likewise, a number of studies and case reports have indicated that passive immunotherapy is a successful therapy for patients suffering chronic relapsing C.difficile infection, which did not respond to standard treatment (i.e., antibiotic therapy). Here in this study we contend that colonizing factor specific IgY preparation, either alone or in combination with other therapeutic strategies, depict for treating CDI because they can be mass-produced inexpensively, and they are listed in a safe category for human use. Passive immunization by oral administration of specific antibodies in a capsule form has been an attractive approach against gastrointestinal tract (GIT) pathogens in both humans and animals. These studies indicate that eggs from chickens immunized with appropriate antigens are potentially a useful of passive immunity. In the future studies the antibody that harvested against antigenic component of C. difficile can be incorporated as prophylactic and passive therapeutic agent. However more intense studies are to be done for successful application of egg derived antibody. 7
  • 8. Dr Sue E Shajan Passive immunotherapy with specific IgY may be a promising alternative with high specific natural and low cost effective. Awards and Honors Lists • PhD Mark List & Degree Certificate. • World Education Service – US equivalency Evaluation Report • Diploma in Medical Microbiology • M.Sc certificates • B.Sc Certificates. Certification • In Charge Of Microbiology Certificate • BLS Certificate • Certificate of Appreciation MOH LAB • CBAHI, JCIA and Quality Control • All Experience Certificates: References Dr. Elizabeth Mathai [WHO Officer, Geneva] Department of Clinical Microbiology CMCH, Vellore. 0041794056602 Relationship: Professor and Mentor for 5 years Dr. A.Michael Department of Microbiology, PSG College of Arts& Science, Coimbatore, Tamil Nadu, India 00919842223414, amichela2000@gmail.com Relationship: Ph.D. Guide for 5 years Dr. M.Palaniswamy Department of Microbiology Karpagam University Coimbatore, Tamil Nadu, India 00919894736777, m.palaniswamy@gmail.com Relationship: Ph.D. Advisor for 5 years Dr. Faisal.H.M Chief of Medical Staff, Department of Medicine, Al Mana General Hospital, 8
  • 9. Dr Sue E Shajan Al Jubail, Saudi Arabia 00966504967427, fahms91@hotmail.com Relationship: Hospital Medical director and Ph.D. Co-guide for total 15 years. Declaration I solemnly declare that the above information furnished here are true to the best of my knowledge and belief. Signature of the Applicant (SUE ELIZABETH SHAJAN) 9
  • 10. Dr Sue E Shajan Al Jubail, Saudi Arabia 00966504967427, fahms91@hotmail.com Relationship: Hospital Medical director and Ph.D. Co-guide for total 15 years. Declaration I solemnly declare that the above information furnished here are true to the best of my knowledge and belief. Signature of the Applicant (SUE ELIZABETH SHAJAN) 9